Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Step-down Therapy After Long-term Osteoporosis Treatment
NCT07281586Phase 4Recruiting
- Sponsor
- National Taiwan University Hospital
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of denosumab in osteoporosis and osteopenia (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Change in Lumbar Spine Bone Mineral Density at 2 years. Started Jan 2026; status: recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on NCT07281586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281586.